Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2023 Earnings Call Transcript

Jeremy Pearlman: Understood. Okay. And then just one last question. Is there any reason to think otherwise why the Hemopurifier would not be able to remove safely and efficaciously. I mean, I get it, it’s just an organ, I don’t know if this is safety. But do we have to remove these exosomes and viruses from the organs blood without – because historically, it’s clear and indicated from many studies and that the Hemopurifier can safely and efficaciously clear these exosomes and viruses from humans. Is there any reason to believe that there should be – do you see it would be otherwise when it comes to the organs?

Steven LaRosa: Right. So you’re right, our past in vitro studies would suggest that there’s a high likelihood that we’ll be able to remove viruses and exosomes. We simply have not done the studies yet on removing those from the perfusate solutions. That have been used – that are being used in those circuits, and that’s a necessary step. But yes, we have high – we think it’s highly likely that those translational studies will bear out that we can remove the viruses and exosomes from the perfusate solution.

Jeremy Pearlman: Okay. Great. It’s an exciting new market opportunity potential. So thank you for taking my question. And I’ll hop back in the queue.

Steven LaRosa: Thank you.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Jim Frakes for any closing remarks.

Jim Frakes: Thank you, everyone, for joining us today to discuss our fiscal year-end results, and we look forward to keeping you up-to-date on future calls. Thanks again. Goodbye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.